IGC Pharma, Inc. Form S-8 10-31-25 - IGC Pharma, INC.

SEC

Filings

October 31, 2025

IGC Pharma, Inc. Form S-8 10-31-25

IGC Pharma, Inc. IGC on NYSE

Related Posts

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

February 23, 2026

IGC Pharma, Inc. 424B5 01-06-26

January 6, 2026

IGC Pharma, Inc 8-K 01-06-26

January 6, 2026

CEO Update

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer’s Trial Approaches Enrollment Closure and Q4 Topline Readout

August 11, 2026

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

July 29, 2026